- Home
- ACRS vs VOXR Comparison
ACRS vs VOXR Comparison
Compare ACRS & VOXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- VOXR
- Stock Information
- Founded
- ACRS 2012
- VOXR 2014
- Country
- ACRS United States
- VOXR United States
- Employees
- ACRS N/A
- VOXR N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- VOXR Precious Metals
- Sector
- ACRS Health Care
- VOXR Basic Materials
- Exchange
- ACRS Nasdaq
- VOXR Nasdaq
- Market Cap
- ACRS 165.7M
- VOXR 168.0M
- IPO Year
- ACRS 2015
- VOXR N/A
- Fundamental
- Price
- ACRS $1.45
- VOXR $3.63
- Analyst Decision
- ACRS Strong Buy
- VOXR
- Analyst Count
- ACRS 8
- VOXR 0
- Target Price
- ACRS $9.71
- VOXR N/A
- AVG Volume (30 Days)
- ACRS 755.2K
- VOXR 300.4K
- Earning Date
- ACRS 08-06-2025
- VOXR 08-06-2025
- Dividend Yield
- ACRS N/A
- VOXR 1.40%
- EPS Growth
- ACRS N/A
- VOXR N/A
- EPS
- ACRS N/A
- VOXR N/A
- Revenue
- ACRS $17,777,000.00
- VOXR $10,845,445.00
- Revenue This Year
- ACRS N/A
- VOXR $16.51
- Revenue Next Year
- ACRS $11.77
- VOXR $4.60
- P/E Ratio
- ACRS N/A
- VOXR N/A
- Revenue Growth
- ACRS N/A
- VOXR N/A
- 52 Week Low
- ACRS $1.05
- VOXR $2.21
- 52 Week High
- ACRS $5.17
- VOXR $3.79
- Technical
- Relative Strength Index (RSI)
- ACRS 51.96
- VOXR 57.19
- Support Level
- ACRS $1.37
- VOXR $3.50
- Resistance Level
- ACRS $1.59
- VOXR $3.71
- Average True Range (ATR)
- ACRS 0.10
- VOXR 0.18
- MACD
- ACRS -0.01
- VOXR -0.00
- Stochastic Oscillator
- ACRS 28.57
- VOXR 73.53
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.